All News

ACR Best

2021 Top Articles from Arthritis & Rheumatology

d ACR

The ACR journal, Arthritis & Rheumatology, has publish a listing of top articles in 2021 as measured by Altmetric, an online service that tracks what gets "clicked" and discussed.  Interestingly, this includes 4 guidelines and 5 COVID-related papers.

Read Article
colitis.jpg

Spondyloarthritis in Early Crohn's Disease

d Jack Cush, MD

Analysis of a German Crohn's disease cohort finds that in patients with early Crohn’s disease (CD), spondyloarthritis was present in nearly one out of five patients and was associated with HLA-B27 positivity and a highly active CD.

Read Article
Lupus,flare,malar,DermNetNZ

Increased SLE Flares with Hydroxychloroquine Reduction

d Jack Cush, MD

Concerns about the long-term safety of hydroxychloroquine (HCQ) often results in dose reduction or drug discontinuation; yet a current study shows that, for those in remission, HCQ taper/discontinuation resulted in a significantly higher rate of SLE flares.

Read Article
Top February Tweet: Positive Results from the DOA (Duloxetine in OsteoArthritis) Study https://t.co/Is56PBxpIr https://t.co/xEh6zbx9nr

Links:

Dr. John Cush RheumNow ( View Tweet)
With H. Zoster on JAK inhib; you can continue JAKi @ low risk. Study of 416 RA pts on JAKi, 8% HZ reactivation (age 60 yrs, 42% Pred) after 11 mos. 72% cont JAKi during HZ, 15% temporarily D/C & resumed. Only 1 pt had HZ re-reactivation https://t.co/dJqhlhGEda

Links:

Dr. John Cush RheumNow ( View Tweet)

Polarized microscopy of synovial fluid to identify uric acid crystals was shown to high utility and reliability in a study of 5 rheumatologists (4 consultants, 1 registrar). 50 SF samples - good agreement w/ κ = 0.71 for MSU, 0.88 for CPP https://t.co/5c7N7spc0t https://t.co/9wXsHuCY6D

Links:

Dr. John Cush RheumNow ( View Tweet)
The worldwide Psoriatic arthritis treatment market is expected to grow from $7.89 billion in 2021 to $8.92 billion in 2022 https://t.co/5gdsUgM08y

Links:

Dr. John Cush RheumNow ( View Tweet)

Pharma payments to rheums. Study of 4822 rheums in Medicare, 77% recv some pharma payment. For every $100 in food/beverage payments, prescribing increased 1.5-14%. For every $1000 in consulting, prescribing increased <5%. https://t.co/tKsRIBbFdt https://t.co/HN2yiTBkPh

Links:

Dr. John Cush RheumNow ( View Tweet)
Phone Calls about Labs How to handle "labs" and expectations. QD Clinic is sponsored by RheumNow Live (March 19 & 20, 2022 in Las Colinas, Texas) https://t.co/WzIGihU1UR https://t.co/uvctRtbUEK

Links:

Dr. John Cush RheumNow ( View Tweet)
INBUILD Study of 170 pts with autoimmune related ILD showed nintedanib signifi. slowed the rate of FVC decline in FVC decline over 52 wks (NIN -75.9 mL/yr vs PBO -178.6 mL/yr). AE's (mostly diarrhea) leading to D/C was NIN 17.1% vs PBO 10.2% https://t.co/VG5oPBU0VC https://t.co/vTkzcwskuJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Diabetes (HR 1.29), bad glycemic control (HR 1.41), and long-term diabetes (>5yrs HR 1.49) are potential risk factors of symptomatic knee OA, independent of age and BMI. Targeting blood glucose, in addition to obesity, may prevent knee OA. https://t.co/6XXVfLumqG https://t.co/ypz8avcjVs

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective study of juvenile dermatomyositis shows 1st line Rx w/ MTX is not effective, esp in MSA Ab+ pts. 45 JDM pts (2/3 severe) Rx w/ 6 mos MTX + steroids; inactive dz seen in 31%, with 42% muscle and 33% skin responses. MSA neg pts did better https://t.co/PDubjbcMe2 https://t.co/rGCSZ3ZT9U

Links:

Dr. John Cush RheumNow ( View Tweet)
Referring Psoriasis with Joint Pain Psoriasis Patient with a Few Tender Joints - How to Refer to a Rheumatologist. QD Clinic is sponsored by RheumNow Live (March 19 & 20, 2022 in Las Colinas, Texas) https://t.co/kuDc6xi3NZ https://t.co/VCFFFqA040

Links:

Dr. John Cush RheumNow ( View Tweet)
Psoriatic fingernail onycholysis and hyperkeratosis, rather than nail pitting, are significantly & independently assoc w/ PsA. Study of 1985 pts w/psoriasis, 11.5% were Dx w/ PsA. Only onycholysis (OR 2.34) and hyperkeratosis ) were assoc w/ PsA https://t.co/X3JHUFtGdD https://t.co/xu8erkOMSa

Links:

Dr. John Cush RheumNow ( View Tweet)
Health Disparities in Rheumatology - a great lecture by Dr. Alvin Wells at RWCS 2022. https://t.co/aZXrKndenF

Links:

Dr. John Cush RheumNow ( View Tweet)

Updated ACR/AAHKS Guidelines on Drug Use in Knee & Hip Arthroplasty Patients https://t.co/e6hSUJDrLK https://t.co/DzgCm47Qyh

Links:

Dr. John Cush RheumNow ( View Tweet)
Downside of Holding MTX with COVID-19 Vax A recent clinical trial has shown that a 2 week hold of MTX following COVID-19 vax resulted in greater anti-SARS-CoV-2 immunogenicity; but there was an increase in flare rates after the second dose of vaccine. https://t.co/a7XfBxVkvJ https://t.co/h4VqsQYkaK

Links:

Dr. John Cush RheumNow ( View Tweet)
Undifferentiated Arthritis +RF Arthralgias x 3 mos and a vague Family History of arthritis. How would you treat? QD Clinic is sponsored by https://t.co/4UQlqwujiR (March 19 & 20, 2022 in Las Colinas, Texas) https://t.co/O0KywLk5dd https://t.co/JV37SGk7ud

Links:

Dr. John Cush RheumNow ( View Tweet)
CRP! Dr John Reveilles review of potential biomarkers in axial spondyloarthritis, includes cytokines, adipokines, MMPs, calprotectin, CD74, bone turnover markers & protein fragments of cartilage degradation - But none can outperform C-reactive protein https://t.co/pmIDZkuOuP

Links:

Dr. John Cush RheumNow ( View Tweet)

🎯Giant cell tumor 🎯denosumab was used to decrease the stage of the local disease prior to surgical resection in 57% of patients #RheumTwitter #Rheumatology #Rheumato #denosumab https://t.co/CBfW3gPvFV https://t.co/pEvo4jUnBH

Links:

Dr.Hala Fadhil MD drhalafadhil ( View Tweet)
×